Adios, Lentigo

Oklahoma City -- Topical application of the immune response modifier imiquimod appears to be an effective and reasonably well-tolerated treatment for lentigo maligna, according to research conducted by dermatologists from the University of Oklahoma Health Sciences Center, Oklahoma City.

Related Videos
Related Content

The Weekly Roundup: March 20-24

March 24th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Highlights from AAD 2023

March 23rd 2023

Vitamin D Supplements During Pregnancy May Reduce Eczema in Infants

March 23rd 2023

The Weekly Roundup: March 20-24

March 24th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Highlights from AAD 2023

March 23rd 2023

Vitamin D Supplements During Pregnancy May Reduce Eczema in Infants

March 23rd 2023

The Weekly Roundup: March 20-24

March 24th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Highlights from AAD 2023

March 23rd 2023

Vitamin D Supplements During Pregnancy May Reduce Eczema in Infants

March 23rd 2023
© 2023 MJH Life Sciences

All rights reserved.